3-(1-(1-(4-((6-amino-8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl)methyl)phenyl)-1-oxo-5,8,11,14,17,20-hexaoxa-2-azadocosan-22-yl)-1H-1,2,3-triazol-4-yl)propanoic acid | 1239692-02-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 3-(1-(1-(4-((6-amino-8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl)methyl)phenyl)-1-oxo-5,8,11,14,17,20-hexaoxa-2-azadocosan-22-yl)-1H-1,2,3-triazol-4-yl)propanoic acid
• 英文别名: 3-(1-(1-(4-((6-amino-8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl)methyl)phenyl)-1-oxo-5,8,11,14,17,20-hexaoxa-2-azadocosan-22-yl)-1H-1,2,3-triazol-4-yl)propionic acid；3-(1-(1-(4-((6-amino-8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl)methyl)phenyl)-1-oxo-5,8,11,14,17,20-hexaoxa-2-azadocos-22-yl)-1H-1,2,3-triazol-4-yl)propanoic acid；3-[1-[2-[2-[2-[2-[2-[2-[2-[[4-[[6-amino-2-(2-methoxyethoxy)-8-oxo-7H-purin-9-yl]methyl]benzoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]propanoic acid
• CAS: 1239692-02-4
• 化学式: C₃₅H₅₁N₉O₁₂
• 分子量: 789.843
• InChiKey: LCQYXTLIUQYJNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  56
• 可旋转键数：
  31
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  255
• 氢给体数：
  4
• 氢受体数：
  17

文献信息

• TREATMENT OF CONDITIONS BY TOLL-LIKE RECEPTOR MODULATORS
  申请人：Holldack Johanna

  公开号：US20120083473A1

  公开（公告）日：2012-04-05

  Provided herein are methods for treating certain conditions, including fibrosis, inflammatory, and autoimmune conditions, with conjugated compounds having Toll-like receptor modulatory activity.
• MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS
  申请人：Nektar Therapeutics

  公开号：US20210128737A1

  公开（公告）日：2021-05-06

  Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods. R Q-POLY-Xr-TLR 7/8 AG) q (I)
• IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD
  申请人：Nektar Therapeutics

  公开号：US20210130467A1

  公开（公告）日：2021-05-06

  Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2Rβ-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.
• [EN] RELIEF FROM OSTEOARTHRITIS PAIN BY TARGETING MICRORNA-21<br/>[FR] SOULAGEMENT DE LA DOULEUR DE L'ARTHROSE PAR CIBLAGE DE MICRO-ARN -21<br/>[JA] ｍｉｃｒｏＲＮＡ－２１を標的とした変形性関節症による疼痛の緩和
  申请人：NIPPON MEDICAL SCHOOL FOUNDATION

  公开号：WO2019176901A1

  公开（公告）日：2019-09-19

  本発明は、変形性関節症における痛みの原因を明確にするとともに、変形性関節症の痛みを緩和する治療薬の開発に寄与することを目的とする。　miR-21阻害薬を有効成分として含む変形性関節症による疼痛の緩和薬、またはTLR拮抗薬を有効成分として含む変形性関節症による疼痛の緩和薬。